APA (7th ed.) Citation

Batra, U., Gupta, V. G., Raut, N., Patil, T., Panchal, H., Ghadyalpatil, N., . . . Biswas, B. (2025). Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India. Thieme Medical and Scientific Publishers Pvt. Ltd.

Chicago Style (17th ed.) Citation

Batra, Ullas, et al. Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India. Thieme Medical and Scientific Publishers Pvt. Ltd, 2025.

MLA (9th ed.) Citation

Batra, Ullas, et al. Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India. Thieme Medical and Scientific Publishers Pvt. Ltd, 2025.